کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5576498 1566104 2016 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی پزشکی و دندانپزشکی (عمومی)
پیش نمایش صفحه اول مقاله
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
چکیده انگلیسی
Oral Factor Xa (FXa) inhibitors, a growing class of direct-acting anticoagulants, are frequently used to prevent stroke and systemic embolism in patients with atrial fibrillation and to prevent and treat venous thromboembolism. These drugs reduce the risk of clotting at the expense of increasing the risk of bleeding, and currently they have no specific reversal agent. However, andexanet alfa, a recombinant modified FXa decoy molecule, is in a late-phase clinical trial in bleeding patients, and ciraparantag, a small molecule that appears to reverse many anticoagulants including the FXa inhibitors, is in development. This review summarizes the published data to date on both drugs, which have the potential to change the management approach to patients with FXa inhibitor-associated major hemorrhage.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: The American Journal of Medicine - Volume 129, Issue 11, Supplement, November 2016, Pages S80-S88
نویسندگان
, , ,